Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results

被引：0

作者：

Oh, J. ^{[1
]}

Syed, S. ^{[2
]}

Orogun, L. ^{[2
]}

Xu, Z. ^{[3
]}

Turner, T. J. ^{[2
]}

Fox, R. J. ^{[4
]}

机构：

[1] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[2] Sanofi, Cambridge, MA USA

[3] Sanofi, Bridgewater, MA USA

[4] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P308

引用

页码：342 / 343

页数：2

共 50 条

[21] Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders - Results of a 2-year extension study
Reyes, M
Olah, R
Csaba, K
Augustyns, I
Eerdekens, M
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2006, 15 (02) : 97 - 104
[22] Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
Journal of Neurology, 2020, 267 : 2851 - 2864
[23] MRI, Efficacy, and Safety of Tolebrutinib in Highly Active Disease: 2-Year Data from Phase 2b Long-term Safety Study
Fox, R.
Oh, J.
Arnold, D.
Syed, S.
Xu, Z.
Turner, T.
Traboulsee, A.
Reich, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 526 - 527
[24] Phase III Long Term Extension Study of Ponesimod in Relapsing Multiple Sclerosis: 5-Year Efficacy Results
Lublin, F. D.
Singh, A.
Ait-Tihyaty, M.
Raghavan, N.
Pirozek-Lawniczek, M.
Sidorenko, T.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 58 - 58
[25] MRI, efficacy, and safety of tolebrutinib in patients with highly active disease (HAD): 2-year data from the phase 2b Long-term safety (LTS) Study
Fox, R. J.
Oh, J.
Arnold, D. L.
Syed, S.
Xu, Z.
Turner, T. J.
Traboulsee, A.
Reich, D. S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 331 - 331
[26] Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Gold, Ralf
Radue, Ernst-Wilhelm
Giovannoni, Gavin
Selmaj, Krzysztof
Havrdova, Eva Kubala
Montalban, Xavier
Stefoski, Dusan
Sprenger, Till
Robinson, Randy R.
Fam, Sami
Smith, Jonathan
Chalkias, Spyros
Giannattasio, Giorgio
Lima, Gabriel
Castro-Borrero, Wanda
JOURNAL OF NEUROLOGY, 2020, 267 (10) : 2851 - 2864
[27] Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study
Vollmer, Timothy
Jeffery, Douglas
Goodin, Douglas
Kappos, Ludwig
Lublin, Fred
Radue, Ernst-Wilhelm
Rammohan, Kottil
Reder, Anthony
Agius, Mark
Stites, Tracy
Li, Bingbing
Cappiello, Linda
von Rosenstiel, Philipp
Calabresi, Peter
NEUROLOGY, 2013, 80
[28] MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study
Fox, Robert
Oh, Jiwon
Arnold, Douglas
Syed, Sana
Xu, Zhixing
Turner, Timothy
Traboulsee, Anthony
Reich, Daniel
NEUROLOGY, 2023, 100 (17)
[29] Long-Term (7-Year) Data from a Phase 2 Extension Study of Fingolimod in Relapsing Multiple Sclerosis
Antel, Jack
Montalban, Xavier
O'Connor, Paul
de Vera, Ana
Cremer, Malika
Sfikas, Nikolaos
Comi, Giancarlo
Kappos, Ludwig
NEUROLOGY, 2012, 78
[30] LONG-TERM SAFETY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Hauser, Stephen
Cross, Anne
Winthrop, Kevin
Wiendl, Heniz
Nicholas, Jacqueline
Meuth, Sven
Giacomini, Paul
Sacca, Francesco
Su, Wendy
Kappos, Ludwig
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):

← 1 2 3 4 5 →